Effect of convalescent plasma in early course of COVID-19 disease
- Conditions
- COVID-19 (SARS-CoV-2 infection)Infections and Infestations
- Registration Number
- ISRCTN49832318
- Lead Sponsor
- Academic Hospital Paramaribo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 210
1. COVID-19 positive patients who have understood and signed the informed consent
2. Aged =18 years
3. Hospital admitted patients with moderate COVID-19 to the non-ICU ward: Laboratory confirmed infection with COVID-19.
1. Severe or life threatening respiratory disease upon admission
2. Viral pneumonia with other viruses besides COVID-19
3. Ineligible for Convalescent Plasma Therapy
4. Participation in other studies.
5. Other circumstances in which the investigator determined that the patient is not suitable for the clinical trial
6. Refusal of informed consent study participation by Donor and/or Patient
7. Known IgA deficiency
8. Medical conditions in which receipt of 220 ml volume may be detrimental to the patient (e.g.decompensated congestive heart failure)
9. Females who are pregnant or breast feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Development of severe respiratory disease, defined as a respiratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% while the patient was breathing ambient air, or both, measured for up to 60 days from baseline.
- Secondary Outcome Measures
Name Time Method